Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 16/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.85 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.64 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.64 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.64 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.64 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.64 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14773087 | 1.00 | APP (0.85) | APPCYP3A4PSEN1PSEN2APH1B | |
| SCHEMBL14753446 | 1.00 | APP (0.85) | APPCYP3A4PSEN1PSEN2APH1B | |
| SCHEMBL14751736 | 1.00 | APP (0.85) | APPCYP3A4PSEN1PSEN2APH1B | |
| SCHEMBL14773101 | 1.00 | APP (0.85) | APPCYP3A4PSEN1PSEN2APH1B | |
| SCHEMBL12209492 | 0.95 | APP (0.84) | APPCYP3A4PSEN1PSEN2APH1B | |
| SCHEMBL12210228 | 0.95 | APP (0.84) | APPCYP3A4PSEN1PSEN2APH1B | |
| SCHEMBL14753587 | 0.94 | APP (0.84) | APPCYP3A4PSEN1PSEN2APH1B | |
| SCHEMBL14755932 | 0.93 | APP (0.85) | APPCYP3A4PSEN1PSEN2APH1B | |
| SCHEMBL14753598 | 0.93 | APP (0.85) | APPCYP3A4PSEN1PSEN2APH1B | |
| SCHEMBL14751774 | 0.92 | APP (1.00) | APPCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130060020-A1 | Compounds useful for treating neurodegenerative disorders | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130060019-A1 | Compounds for Use in Treating Neurodegenerative Disorders, Synthesis Thereof, and Intermediates Thereto | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060020-A1 | Compounds useful for treating neurodegenerative disorders | SNCA, HTT, SMN1; SMN2 | APP 40/4885CYP3A4 4150/4885PSEN1 9/4885 |
| US-20130060019-A1 | Compounds for Use in Treating Neurodegenerative Disorders, Synthesis Thereof, and Intermediates Thereto | SNCA, HTT, PARK7 | APP 15/4885CYP3A4 1228/4885PSEN1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.